Abstract
Oxidative stress is a distinguishing feature in atherosclerosis disease. Reactive oxygen species (ROS) can increase the oxidized low density lipoprotein (ox-LDL) and oxidative damage to macrophages in the plaque. Although antioxidant agents such as N-acetylcysteine are used to treat atherosclerosis, but provide a poor clinical benefit to the majority of patients with atherosclerosis. Here we have designed hyaluronic acid-guided assemblies of ceria nanozymes (HA-CeO2 NPs) as novel plaque-targeting ROS scavengers. The introduction of hyaluronic acid not only provide the stability and biocompatibility, but also surprisingly enhance SOD-mimic activities of ceria nanozymes compared to bare CeO2 precipitates, dextran or poly-aspartic acid coated ceria nanozymes. Interestingly, we find HA-CeO2 NPs not only actively target plaque-associated macrophages in atherosclerosis to remove superfluous ROS and protect macrophages from ROS-caused damages, but also effectively inhibit endocytosis of ox-LDL by activated macrophages. We believe HA-CeO2 nanozymes can serve as a simple and promising platform for anti-atherosclerotic therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
